ECTS2014 Poster Presentations Osteoporosis: treatment (68 abstracts)
Risk factors for the development of chronic back pain after percutaneous vertebroplasty vs conventional treatment
Pilar Peris 1, , Jordi Blasco 2 , Josep L Carrasco 3 , Angels Martinez-Ferrer 1 , Juan Macho 2 , Luis San Roman 2 , Ana Monegal 1 & Nuria Guañabens 1,
1Rheumatology Department, Hospital Clinic, Barcelona, Spain;
2Neurointerventional Department, Hospital Clinic, Barcelona, Spain; 3Public Health Department, University of Barcelona, Barcelona, Spain; 4CIBERehd, Barcelona, Spain.
In a recent randomized controlled trial comparing vertebroplasty (VP) vs conservative treatment (CT) in patients with symptomatic vertebral fractures (VF) we observed the development of severe chronic back pain (CBP) in nearly one quarter of patients. The aim of this study was to evaluate the risk factors related to the development of CBP in these subjects.
Methods: We evaluated risk factors including: visual analog scale (VAS) at baseline and during the 1-year follow-up, age, gender, symptom-onset time, number, type and severity of VF at baseline, number of vertebral bodies treated, incident VF, and antiosteoporotic treatment, among others. CBP was considered in patients with VAS ≥7 at 12 months.
Results: 91/125 patients completed the 12-month follow-up. CBP was observed in 23% of VP-treated patients vs. 23% receiving CT. Patients developing CBP after VP showed a longer symptom-onset time (82%≥4 months in VP vs 40% in CT, P=0.03). On univariate analysis, female gender (OR 1.52; 95% CI 1.47–1.57, P<0.0001), multiple acute VF (OR 1.79; 95% CI 1.71–1.87, P<0.0001), VAS ≥7 2 months after treatment (OR 11.04;95% CI 6.71–18.17, P<0.0001) and type of antiosteoporotic drug (teriparatide) (OR 0.12; 95% CI 0.03–0.60, P=0.0236) were risk factors of CBP development in both groups. In the multivariate analysis the main risk factors were baseline and post-treatment VAS ≥7, longer symptom-onset time and type of antiosteoporotic treatment.
Conclusions: 23% of patients with symptomatic osteoporotic VF developed severe CBP independently of the type of treatment. Symptom-onset time before VP and persistence of severe CBP after treatment were the main factors related to CBP with teriparatide treatment decreasing the risk of this complication.
Article tools
My recent searches
My recently viewed abstracts
Authors
Bone Abstracts
ISSN 2052-1219 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more